Abstract: A touch panel system includes a touch panel, a cover member overlapping the touch panel, and a controller. The controller includes a position detection unit configured to detect a position of a pointer, based on a signal value obtained from a position detection electrode, an amplification processing unit configured to perform amplification processing on at least one signal value in a pressing force detection range corresponding to the position of the pointer detected by the position detection unit among signal values obtained from a pressing force detection electrode, and a pressing force detection unit configured to calculate magnitude of a pressing force generated by the pointer, based on a signal value after the amplification processing being a signal value in the pressing force detection range including a signal value obtained by amplification by the amplification processing unit.

Abstract: A touch panel system includes a capacitive touch panel and a controller that controls the touch panel. The touch panel includes drive electrodes and floating island electrodes located on a first substrate and position detection electrodes, pressure detection electrodes, and heat detection electrodes located on a second substrate. The drive electrode overlaps at least part of the heat detection electrode and at least part of the pressure detection electrode, and the floating island electrode overlaps at least part of the position detection electrode in plan view. The controller provides a drive signal to the drive electrodes and the heat detection electrodes and corrects a pressure detection signal obtained from each of the pressure detection electrodes by using a heat detection signal obtained from a change in a coupling capacitance between the pressure detection electrode and the heat detection electrode.

Abstract: The object of the present invention is to improve the solubility of sphingoglycolipids having low solubility in water. Disclosed is a lyophilized composition comprising the &agr;-glycosylceramide represented by the following formula (A) or a salt thereof, a polyoxysorbitan fatty acid ester and disaccharide or monosaccharide, and preferably additional deoxycholic acid or histidine, and a process for preparing it: wherein R1 represents H or OH; X denotes an integer in the range of 7-25; R2 represents any one of the substituents —CH2(CH2)YCH3, —CH(OH)(CH2)YCH3, —CH(OH)(CH2)YCH(CH3)2, —CH═CH(CH2)YCH3, or —CH(OH)(CH2)YCH(CH3)CH2CH3, wherein Y denotes an integer in the range of 5-17; either one of R3 or R4 represents H, and the other represents H, OH, NH2 or NHCOCH3; either one of R5 or R6 represents H, and the other represents OH; either one of R7 or R8 represents H, and the other represents OH; R9 represents H, CH3 or CH2OH.

Abstract: The object of the present invention is to improve the solubility of sphingoglycolipids having low solubility in water.

Abstract: An oral dosage form comprising: (a) granulocyte colony stimulating factor or erythropoietin; (b) surfactant(s); (c) fatty acid(s); and (d) enteric material. The oral drug preparations provided by the present invention avoid inactivation of the principal ingredient during the process of pharmaceutical manufacturing and display enhanced absorption of the ingredient from the intestinal tract, particularly as a result of the addition of fatty acid(s) to the drug composition. As such, oral dosage forms of the present invention can allow for dosage reductions, facilitate accurate dose control, and increase the practical usefulness of the bioactive proteins.